HDT BIO corp - AOI #21 vaccine on demand: r & d use of lion-reprna in rapid response vaccine development
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50123C00051
- Awardee
-
HDT Bio Corp UEI Z33DCMWXZBK7
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $749,000
Award facts
- Opportunity
-
- BAA22100SOL00003 Solicitation number
- Contract value 100% obligated
- $749,000.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Seattle, WA 98102, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a $749,000 firm fixed-price definitive contract to HDT Bio Corp on September 22, 2023, for research and development activities related to "Vaccine on Demand" utilizing the company's LION-RepRNA (lipid inorganic nanoparticle self-replicating RNA) technology in rapid response vaccine development. The contract, which carries no set-aside designation, is scheduled for completion by April 30, 2025, and will be performed at HDT Bio Corp's Seattle, Washington facility. This engagement aligns with ASPR's mission to enhance the nation's preparedness and response capabilities for public health emergencies by advancing innovative vaccine technologies that can be rapidly deployed in response to emerging infectious disease threats.
HDT Bio Corp, a Seattle-based biopharmaceutical company with expertise in RNA-based vaccine development and delivery platforms, brings specialized capabilities in self-replicating RNA technologies and lipid nanoparticle formulations to this effort. The company has established a track record of federal partnership through multiple contracts and grants focused on vaccine development and infectious disease solutions, including prior awards from the National Institute of Allergy and Infectious Diseases and ASPR. This contract represents a continuation of the government's investment in HDT Bio Corp's proprietary LION-RepRNA platform as a strategic tool for accelerating vaccine development timelines during public health emergencies.
Quick answers
Who was awarded contract 75A50123C00051?
75A50123C00051 was awarded to HDT Bio Corp by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 22, 2023.
How much is contract 75A50123C00051 worth?
The government has obligated $749,000 on 75A50123C00051.
Was contract 75A50123C00051 competed?
The extent of competition for 75A50123C00051 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award